Natasha Burke
Overview
Explore the profile of Natasha Burke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
770
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanchorawala V, Barroso B, Shelton A, Goetz E, Mendelson L, Joshi T, et al.
Blood Adv
. 2024 Sep;
8(22):5826-5828.
PMID: 39293090
No abstract available.
2.
Staron A, Mendelson L, Joshi T, Burke N, Sanchorawala V
Br J Haematol
. 2024 Sep;
205(6):2268-2272.
PMID: 39275899
Patients with AL amyloidosis can have persistent organ dysfunction despite achieving a haematological complete response (hemCR). We aimed to identify factors for organ non-response among 143 patients who achieved hemCR...
3.
Anand S, Staron A, Mendelson L, Joshi T, Burke N, Sanchorawala V, et al.
Am J Hematol
. 2024 Sep;
99(11):2140-2151.
PMID: 39257247
Immunoglobulin light chain (AL) amyloidosis is a multisystem disease with varied treatment options and disease-related outcomes. Current staging systems rely on a limited number of cardiac, renal, and plasma cell...
4.
Mackinnon E, Leiter L, Wani R, Burke N, Shaw E, Witges K, et al.
Cardiol Ther
. 2024 Jan;
13(1):205-220.
PMID: 38285331
Introduction: The 2021 Canadian Cardiovascular Society (CCS) guidelines recommend intensive low-density lipoprotein cholesterol (LDL-C) reduction for patients with atherosclerotic cardiovascular disease (ASCVD). For patients above LDL-C threshold on maximally tolerated...
5.
Goeree R, Burke N, Jobin M, Brown J, Lawrence D, Stollenwerk B, et al.
Arch Osteoporos
. 2022 Apr;
17(1):71.
PMID: 35471711
Purpose: To demonstrate the value of romosozumab sequenced to alendronate compared to alendronate or risedronate alone, for the treatment of osteoporosis in postmenopausal women with a history of osteoporotic fracture...
6.
Schemitsch E, Adachi J, Brown J, Tarride J, Burke N, Oliveira T, et al.
Osteoporos Int
. 2021 Aug;
33(1):113-122.
PMID: 34379148
Purpose: This large retrospective cohort study aimed to provide hip fracture data, in the context of other fractures, to help inform efforts related to hip fracture prevention focusing on post-fracture...
7.
Adachi J, Brown J, Schemitsch E, Tarride J, Brown V, Bell A, et al.
BMC Musculoskelet Disord
. 2021 Feb;
22(1):224.
PMID: 33637078
Background: The secondary fracture prevention gap in the osteoporosis field has been previously described as a 'crisis'. Closing this gap is increasingly important in the context of accumulating evidence showing...
8.
Brown J, Adachi J, Schemitsch E, Tarride J, Brown V, Bell A, et al.
BMC Musculoskelet Disord
. 2021 Jan;
22(1):105.
PMID: 33485305
Background: Recent studies are lacking reports on mortality after non-hip fractures in adults aged > 65. Methods: This retrospective, matched-cohort study used de-identified health services data from the publicly funded...
9.
Tarride J, Luong T, Goodall G, Burke N, Blackhouse G
Clinicoecon Outcomes Res
. 2019 Sep;
11:477-486.
PMID: 31551658
The treatment of severe aortic stenosis requires replacement of the defective native valve. Traditionally, this has been done via surgery, but in the last 10 years, transcatheter techniques have emerged....
10.
OReilly D, Blackhouse G, Burns S, Bowen J, Burke N, Mehltretter J, et al.
Clinicoecon Outcomes Res
. 2018 Dec;
10:655-663.
PMID: 30498367
Objective: The aim of this study was to evaluate the impact of pharmacist administration of influenza vaccine in Ontario on: 1) vaccination-associated costs related to the number of people vaccinated;...